Peripheral Arterial Disease (PAD) Therapeutics

Global Market Trajectory & Analytics

MCP-6815

EXECUTIVE ENGAGEMENTS

POOL

2014
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

363
Interactions with Platform & by Email

PARTICIPANTS

62
Unique # Participated

VALIDATIONS

18
Responses Validated*

COMPANIES

23
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

32

PAGES

85

EDITION

16

PRICE

USD 5450

CODE

MCP-6815


COMPETITIVE METRICS

COMPANY

RANK & SHARE

D S N T

% *

480 Biomedical

Login Required

ActivBiotics

Login Required

AstraZeneca PLC

Login Required

AtheroMed

Login Required

Bayer AG, Pharmaceuticals

Login Required

Beijing Tide Pharmaceutical Co., Ltd.

Login Required

Betagenon AB

Login Required

CardioVascular BioTherapeutics, Inc.

Login Required

Cardiovascular Systems

Login Required

Cytovas

Login Required

SUBMIT
* D = Dominant; S = Strong; N = Niche; T = Trivial (< 1%)
* Validated participants will receive complimentary Cluster data by email
Note: Best viewed in Landscape Mode
VIEW ENTIRE POOL OF 23 COMPETITORS

Sign-in with email to View Deeper Validated Engagement Details -

  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Peripheral Arterial Disease (PAD) Therapeutics estimated at US$776.4 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing at a CAGR of 4.7% over the period 2020-2027.
The Peripheral Arterial Disease (PAD) Therapeutics market in the U.S. is estimated at US$228.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$189.1 Million by the year 2027 trailing a CAGR of 4.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.5% and 3.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

SELECT PLAYERS

AstraZeneca Plc.; Bayer HealthCare Pharmaceuticals; Bristol-Myers Squibb Company; Merck & Co., Inc.; Proteon Therapeutics, Inc.; Sanofi S.A.; Symic Bio, Inc.; TheraVasc, Inc.

SEGMENTS

» Segment (Peripheral Arterial Disease (PAD) Therapeutics)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
PAD - A Prelude
Recent Market Activity
PAD Statistics
Critical Limb Ischemia - An Insight
High Costs - A Cause of Concern
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)
3. MARKET TRENDS & DRIVERS
Aging - A Key Driver
High Diabetes Incidence Worldwide: Key Market Opportunity for PAD Therapeutics
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
CANADA
Canada Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
JAPAN
Japan Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
CHINA
China Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
EUROPE
Europe Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
GERMANY
Germany Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
ITALY
Italy Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UNITED KINGDOM
UK Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
REST OF EUROPE
Rest of Europe Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
REST OF WORLD
Rest of World Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Segment - Peripheral Arterial Disease (PAD) Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Total Companies Profiled: 23

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com